This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… platform for the exchange and sharing of insights and innovations to drive the future of clinical development in … platform for the exchange and sharing of insights and innovations to drive the future of clinical development in …
… Unlocking the Potential of Innovative Editing Oligonucleotides to Address Liver … Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive … and development and is currently in charge of our Innovation unit. Axiomer ® , an RNA editing platform, uses …
… of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our … developing the medicines of tomorrow takes time, sustained innovation and most importantly, collaboration. Andrew C. …
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … uncommon problems and critical about own work Passion for innovation and drive to deliver new therapies to patients …
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … integration and alignment of research efforts, driving innovation and efficiency in drug development. Proactively …
